Interval Versus Continuous Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease

Interval Versus Continuous Exercise Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease: a Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02168712

Enrollment

Registered

2014-06-20

Start date

2011-11-30

Completion date

2014-04-30

Last updated

2014-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

Coronary Heart Disease, Interval exercise training, Continuous exercise training, Quality of life, Safety

Brief summary

Exercise therapy increase functional capacity improving the morbidity and mortality of patients with cardiovascular disease. Moderate continuous training is the best established training modality for this patients. However, a body of evidence has begun to emerge demonstrating that high intensity interval training obtained better results in terms of morbidity and mortality. The purpose of this randomized clinical trial was to determine the effect of two types of exercise training: moderate continuous training vs high interval training on functional capacity and quality of life as well as verify the safety in its application. We included 72 patients with coronary artery disease by assigning one of the training modality for 8 weeks. We analyzed cyclo-ergo-spirometry data, aspect related to quality of life as well as a record of adverse events.

Interventions

OTHERModerate continuous exercise training

OTHERInterval exercise training

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Coronary heart Disease, with functional class II-III according to New York Heart Association classification system. * At least 4 weeks from acute cardiac event, percutaneous or surgery revascularization. * Optimized medical treatment in adequate doses ( betablockers, ACE inhibitors, ARA II, statins and antiplatelet drugs) * Age \> 18 years old. * Willing to participate and sign an informed consent form

Exclusion criteria

* Residual ischemia waiting for revascularization. * Any cardiac event for the last 4 weeks * Abnormal Ergometry with hemodynamic or clinically significant arrhythmias during the procedure. * History of severe ventricular arrhythmia * Uncontrolled glycaemia or blood pressure * Moderate to severe Chronic Pulmonary Obstructive Disease * Osteomuscular and/or mental disorder that hampers an adequate adherence to the intervention program * Other vascular diseases: rheumatologic/ autoimmune disorders, thrombopathies, hemophilia. * Active oncologic disease. * Treatment with corticosteroids.

Design outcomes

Primary

Measure	Time frame	Description
Impact on functional capacity	2 months	Basal and peak oxygen consumption values will be measured.

Secondary

Measure	Time frame	Description
quality of life	2 months	Quality of life will be compared between the two arms with one generic questionnaire (SF-36) and one ischemic heart disease specific questionnaire (MacNew)

Other

Measure	Time frame	Description
Incidence of Adverse Events	2 months	The incidence of cardiovascular adverse events in each group will be compared

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026